[LCID Study Number: 2015-063]
Molecular Analysis for Therapy Choice (MATCH)
The primary objective of this study is to evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced cancers/lymphomas/multiple myeloma. Researchers will evaluate the proportion of patients progression free at 6 months of treatment with targeted study agents.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-2734